CVS Health's poor 2024 performance could be turning around in 2025 with a new CEO and potential rebound, despite challenges.
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...
Hosted on MSN8h
UnitedHealth's OptumRx Accused of Excessive Drug PricingThe Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Latin Times on MSN16h
UnitedHealth Is Price Gouging Cancer Patients by Overcharging 'Thousands of Percent' for Live-Saving Meds, Pocketing Extra Billions: FedsThe UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases ...
Hosted on MSN11h
Report Reveals Billions Made from Generic Drug Price HikesA recent Federal Trade Commission report highlights a concerning trend in the pharmaceutical industry, where pharmacy benefit ...
UnitedHealth Group (UHG) has been overcharging some cancer patients by more than 1,000 percent for live-changing drugs, a ...
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
SAN FRANCISCO (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its ...
CVS Health shares are trading lower by 2.7% during Thursday's session. Shares of insurers and pharmacy benefit manager stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback